Phio Pharmaceuticals Corp. (PHIO)
| Market Cap | 24.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.85M |
| Shares Out | 10.68M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | 1.10 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $1.84 |
| Previous Close | $1.82 |
| Change ($) | 0.02 |
| Change (%) | 1.10% |
| Day's Open | 1.82 |
| Day's Range | 1.77 - 1.87 |
| Day's Volume | 97,744 |
| 52-Week Range | 1.72 - 4.36 |
MARLBOROUGH, Mass., July 7, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
MARLBOROUGH, Mass., June 22, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., June 14, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., June 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
MARLBOROUGH, Mass., May 13, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
Phio Pharmaceuticals Corp (NASDAQ: PHIO) stock falls despite the company announcing positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cel...
MARLBOROUGH, Mass., May 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
Reddit penny stocks continue to see momentum; here's 4 to watch with higher than average volume The post 4 Hot Reddit Penny Stocks With Higher Than Average Volume appeared first on Penny Stocks to Buy, ...
MARLBOROUGH, Mass., April 29, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...
Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced new preclinical data for the Intasyl platform in tumor settings. These data were presented today during the AACR Annual Meeting 2021.
MARLBOROUGH, Mass., April 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...
MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...
MARLBOROUGH, Mass., March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has entered into a clinical development collaboration with AgonOx Inc to develop novel T cell-based cancer immunotherapies. The collaboration will use Phio's lea...
MARLBOROUGH, Mass., Feb. 23, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Feb. 17, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Jan. 25, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Jan. 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
MARLBOROUGH, Mass., Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Nov. 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Nov. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 12, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares more than doubled on Friday after the firm announced positive data from its cancer study at the American Society of Clinical Oncology (ASCO) 2020 Virtual...
MARLBOROUGH, Mass., May 14, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
About PHIO
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which... [Read more...]
| Industry Biotechnology | |
| CEO Gerrit Dispersyn | Employees 10 |
| Stock Exchange NASDAQ | Ticker Symbol PHIO |
Analyst Forecasts
According to one analyst, the rating for PHIO stock is "Buy" and the 12-month stock price forecast is 6.00.